

Advancing therapies

Cardiovascular
risk management

Diabetes
complications

High bleeding
risk management



Advancing therapies

BARCELONA

XLIV ERA-EDTA CONGRESS

Centre Convencions
Internacional Barcelona (CCIB)

Industry symposium

Saturday, June 23, 2007
12:00 - 13:30
Room 111 (Barceloneta)
Level 1

HOSPAL
www.hospal.com

Global Marketing - In-Center Care
61, avenue Tony Garnier
69007 Lyon France
Tel.: +33 (0)4 37 28 10 00
Fax: +33 (0)4 37 28 11 01

HCEN4727_1 © 2007, Gambro Industries

HOSPAL

Barcelona

XLIV ERA-EDTA CONGRESS

Saturday, June 23, 2007

Industry symposium

12:00 - 13:30

Room 111 (Barceloneta), Level 1

Survival benefits of Acetate-Free Biofiltration (AFB). *Results from the first-ever randomised multicentre study*

Program

Chairmen:

Dr. Giovanni Panzetta (*Trieste, Italy*)

Dr. Rafael Perez (*Madrid, Spain*)

Introduction and welcome

Dr. Giovanni Panzetta (Trieste, Italy)

Purpose and benefits of a survival trial on AFB therapy

Prof. Volker Wizemann (Giessen, Germany)

Results from the first-ever prospective, randomised, multicentre study

Dr. Antonio Santoro (Bologna, Italy)

What can we learn from the results?

Dr. Bruno Perrone (Saintes, France)

Concluding remarks and discussion

Dr. Rafael Perez (Madrid, Spain)